Nová – přímá perorální antikoagulancia: aktuální přehled

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English New – direct oral anticoagulants: actual review
Authors

MICHALCOVÁ Jana PENKA Miroslav BULIKOVÁ Alena ZAVŘELOVÁ Jiřina ŠTĚPAŘOVÁ Andrea

Year of publication 2016
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords apixaban; dabigatran; DOAC; NOAC; rivaroxaban
Description In recent years the options of anticoagulant/antithrombotic therapy have extended with new – direct oral anticoagulants, comprising direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban). These agents represent another progress towards “the ideal antithrombotic drug“, and thus towards a safe and effective antithrombotic therapy. The following article provides actual review and recommendations for clinical practice, including laboratory assessment and management of emergency situations. The approval of idarucizumab as a specific antidote for dabigatran has marked an important step in safety of this treatment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.